<DOC>
	<DOCNO>NCT01094288</DOCNO>
	<brief_summary>This open-label , multicenter , Phase 1 study evaluate safety tolerability MLN8237 give orally combination docetaxel treatment advance solid tumor determine tolerable dos schedule MLN8237 docetaxel evaluate future Phase 2 study .</brief_summary>
	<brief_title>A Phase 1 Study MLN8237 Patients With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving Standard Docetaxel Regimen</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion enrol study : 18 year old Histologically cytologically confirm advanced tumor candidate docetaxel treatment Measurable evaluable disease require . Patients must clinical evidence progressive disease persistent disease Patients castrationresistant prostate cancer ( CRPC ) require Pathologically confirm adenocarcinoma prostate Evidence metastatic disease bone scan imaging . Patients PSA elevation manifestation disease eligible . Progressive disease least 1 hormonal treatment document testosterone level less 50 ng/dl Concurrent use agent testosterone suppression ( e.g. , LHRH agonist ) require patient surgically castrated Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Recovered less equal Grade 1 toxicity ( CTCAE ) , patient 's baseline status ( except alopecia ) deem irreversible effect prior cancer therapy must evidence progressive persistent disease Adequate bone marrow , liver renal function Any use opiate must stable least 2 week prior study entry Female patient postmenopausal least 1 year OR surgically sterile OR childbearing potential , agree practice 2 effective method contraception time Male patient agree practice effective barrier contraception entire study 6 month last dose study drug OR agree abstain heterosexual intercourse Voluntary write consent Willing comply schedule visit , treatment plan , laboratory test trial procedure Suitable venous access blood sample Patients meet follow exclusion criterion enrol study : Female patient lactate pregnant Antineoplastic therapy experimental therapy within 21 day first dose MLN8237 Prior current investigational therapy within 4 week first dose MLN8237 Concurrent investigational treatment treatment investigational product within 28 day first dose MLN8237 Radiotherapy great 40 % bone marrow radiotherapy ( except localize , small field radiation ) within 4 week prior enrollment , unless review approve medical monitor Nitrosoureas mitomycinC within 6 week first dose MLN8237 . Autologous stem cell transplant within 3 month first dose MLN8237 , prior allogeneic stem cell transplant time . Use enzymeinducing antiepileptic drug phenytoin , carbamazepine phenobarbital , rifampin , rifabutin , rifapentine St. John 's wort within 14 day prior first dose MLN8237 For CRPC patient : Radiotherapy antiandrogen therapy prostate cancer within 4 week prior enrollment Prior treatment antineoplastic chemotherapy radioisotope advance prostate cancer Use product know affect PSA level within 4 week enrollment Major surgery within 4 week study enrollment Uncontrolled high blood pressure Patients abnormal gastric bowel function require continuous treatment antacid proton pump inhibitor Patients receive chronic steroid therapy follow : low dose steroid control nausea vomiting , topical steroid , inhale steroid use dexamethasone Known severe hypersensitivity docetaxel drug formulate polysorbate 80 Comorbid condition unresolved toxicity would preclude administration docetaxel Prior history Grade 2 great neurotoxicity toxicity resolve Grade 1 Symptomatic brain CNS metastasis Diagnosis treatment another malignancy within 2 year precede first dose study drug except nonmelanoma skin cancer situ malignancy completely resect Known history human immunodeficiency virus ( HIV ) infection , hepatitis B , hepatitis C Patients require full systemic anticoagulation Prior allogeneic bone marrow organ transplant Active infection require systemic therapy within 14 day precede first dose , serious infection History hemorrhagic thrombotic cerebrovascular event past 12 month Serious medical psychiatric illness could interfere protocol completion Inability swallow oral medication Prior treatment 3 myelosuppressive cytotoxic chemotherapy regimens Prior treatment 1 prior taxanecontaining regimen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>